Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 Sep 22;211(10):1925–1935. doi: 10.1084/jem.20140131

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2014 Boyd et al.

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).

PMC Copyright notice

Figure 4. — Leukemia mobilization facilitates competitive reconstitution by subsequent HSPC transplants at the expense of leukemic self-renewal. (A) Experimental design to test whether mobilization treatment of established AML grafts can facilitate competitive reconstitution by subsequent HSPC transplants (CB Lin⁻ cells). (B) Representative flow cytometry plots gated on human CD45⁺ populations. Gate frequencies indicate percent CB composition of human grafts (blue gates). (C) Summary of absolute human CB and leukemic engraftment levels showing that the total AML engraftment of three individual patients is reduced after mobilization-primed HSCT (n = 4–5 per group for each patient). Engraftment values are gated within all live events in BM. *, P < 0.05, unpaired Student’s t test. (D) Experimental design to test whether mobilization treatment of established CB grafts can facilitate competitive reconstitution by subsequent healthy HSPC transplants. (E) Summary of absolute donor-specific engraftment levels showing that the chimerism levels of initial healthy donor grafts are reduced after mobilization-primed HSPC transplantation (n = 4 per group). Engraftment values are gated within all live events in BM. **, P < 0.01, unpaired Student’s t test. (F) Experimental design to test whether mobilization treatment of established CB grafts can facilitate competitive reconstitution by subsequent AML transplantation. (G) Summary of absolute human CB and leukemic engraftment levels showing that the chimerism levels of initial healthy donor grafts are reduced after mobilization-primed AML transplantation (n = 4 per group). Engraftment values are gated within all live events in BM. *, P < 0.05, unpaired Student’s t test. (H) Experimental design to assess the self-renewal potential of primary human AML grafts that were exposed to competitive repopulation by healthy HSPCs either with or without premobilization of leukemic cells. (I) Representative flow cytometry plots gated on human CD45 showing preferential self-renewal of HSPCs at the expense of AML L-ICs after mobilization-conditioned HSCT of leukemic mice. Gate frequencies indicate percent CB composition of human grafts (blue gates).